This prospective clinical case series aimed to investigate the safety and efficacy of suprachoroidal adipose tissue-derived mesenchymal stem cell (ADMSC) implantation in patients with dry-type age-related macular degeneration (AMD) and Stargardt's macular dystrophy (SMD). This study included four patients with advanced-stage dry-type AMD and four patients with SMD who underwent suprachoroidal implantation of ADMSCs. The best-corrected visual acuity (BCVA) in the study was 20/200. The worse eye of the patient was operated on. Patients were evaluated on the first day, first week, and first, third, and sixth months postoperatively. BCVA, anterior segment and fundus examination, color photography, fundus autofluorescence, optical coherence tomography, and visual field examination were carried out at each visit. Fundus fluorescein angiography and multifocal electroretinography (mf-ERG) recordings were performed at the end of the first, third, and sixth months and anytime if necessary during the follow-up. All eight patients completed the sixth month follow-up. None of them had any systemic or ocular complications. All of the eight patients experienced visual acuity improvement, visual field improvement, and improvement in mf-ERG recordings. Stem cell treatment with suprachoroidal implantation of ADMSCs seems to be safe and effective in the treatment of dry-type AMD and SMD.

中文翻译：

---

干性年龄相关性黄斑变性和Stargardt黄斑营养不良患者的脉络膜上脂肪组织来源的间充质干细胞植入：2期研究的6个月随访结果。

该前瞻性临床病例系列旨在研究在患有干性年龄相关性黄斑变性（AMD）和Stargardt黄斑营养不良（SMD）的患者中，脉络膜上脂肪组织间充质干细胞（ADMSC）植入的安全性和有效性。这项研究包括4例晚期干型AMD患者和4例接受ADMSCs脉络膜上植入的SMD患者。在研究中，最佳矫正视力（BCVA）为20/200。病人的眼睛较差。在术后的第一天，第一周以及第一，第三和第六个月对患者进行评估。每次访视时进行BCVA，前段和眼底检查，彩色摄影，眼底自发荧光，光学相干断层扫描和视野检查。在第一个月，第三个月和第六个月结束时进行眼底荧光血管造影和多焦点视网膜电图（mf-ERG）记录，必要时在随访期间随时进行。所有八名患者均完成了第六个月的随访。他们都没有全身或眼部并发症。八名患者中的所有患者均经历了视力改善，视野改善以及mf-ERG记录改善。用干脉络膜上植入ADMSCs进行干细胞治疗在治疗干型AMD和SMD中似乎是安全有效的。八名患者中的所有患者均经历了视力改善，视野改善以及mf-ERG记录改善。用干脉络膜上植入ADMSCs进行干细胞治疗在治疗干型AMD和SMD中似乎是安全有效的。八名患者中的所有患者均经历了视力改善，视野改善以及mf-ERG记录改善。用干脉络膜上植入ADMSCs进行干细胞治疗在治疗干型AMD和SMD中似乎是安全有效的。